Rain Therapeutics, Inc. (RAIN)

NASDAQ: RAIN · IEX Real-Time Price · USD
8.01
+0.33 (4.30%)
Aug 12, 2022 4:00 PM EDT - Market closed
4.30%
Market Cap 212.78M
Revenue (ttm) n/a
Net Income (ttm) -71.42M
Shares Out 26.56M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 66,509
Open 7.78
Previous Close 7.68
Day's Range 7.76 - 8.25
52-Week Range 2.15 - 18.78
Beta n/a
Analysts Buy
Price Target 18.87 (+135.6%)
Earnings Date Aug 4, 2022

About RAIN

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including b... [Read more...]

Industry Biotechnology
IPO Date Apr 23, 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol RAIN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RAIN stock is "Buy." The 12-month stock price forecast is 18.87, which is an increase of 135.58% from the latest price.

Price Target
$18.87
(135.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 –

UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –

Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022

NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report finan...

Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress

– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 –

Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report fina...

Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Resea...

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentati...

Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress

– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarc...

Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments

– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations –

Rain Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellank...

Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors...

The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors The interventional, multicente...

Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022

Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan

The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease

Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report finan...

Rain Therapeutics Hosting Research and Development (R&D) Day

Tuesday, November 9th at 11:00 am ET Tuesday, November 9th at 11:00 am ET

Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference ...

Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Presentations hi...

Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellan...

Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellank...

Rain Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (“DD”) liposarcoma (“LPS”)

Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial resul...

4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month

In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outper...

Other symbols: HOWL

Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021

Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, ...

Rain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress

Completed initial public offering ("IPO") with net proceeds of $121.9 million

Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President

Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer